Total synthesis and biological mode of action of largazole: A potent class I histone deacetylase inhibitor

Journal of the American Chemical Society

Volumn 130, Issue 33, 2008, Pages 11219-11222

  Bowers, Albert ^a   West, Nathan ^c   Taunton, Jack ^d   Schreiber, Stuart L ^e   Bradner, James E ^c   Williams, Robert M ^a,b  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CHEMOTHERAPY; DRUG DELIVERY; DRUG DOSAGE;

ACID MOIETY; CELL LINES; CELL PERMEABILITY; CLASS I; CYTOTOXIC; CYTOTOXIC ACTIVITIES; HISTONE DEACETYLASE INHIBITORS; MODE OF ACTION; TOTAL SYNTHESIS;

METABOLITES;

HISTONE DEACETYLASE INHIBITOR; LARGAZOLE; ROMIDEPSIN; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MEMBRANE PERMEABILITY; CYTOTOXICITY; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MELANOMA CELL;

CELL LINE, TUMOR; CELL PROLIFERATION; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MOLECULAR CONFORMATION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFHYDRYL COMPOUNDS; THIAZOLES;

EID: 50249144006     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja8033763     Document Type: Article

References (38)

1. (a) Taori, K.; Paul, V. J.; Luesch, H. J. Am. Chem. Soc. 2008, 130, 1806-1807.
2. (b) Subsequent to the submission of the present manuscript on May 6, 2008, Luesch et al. independently published a distinct synthesis of largazole: Ying, Y.; Taori, K.; Kim, H.; Homg, J.; Luesch, H. J. Am. Chem. Soc. 2008, 130, 8455-8459.
3. (a) Fujisawa Pharmaceutical Co., Ltd. Jpn. Kokai Tokkyo Koho JP,03141296, 1991.
4. (b) Ueda, H.; Nakajima, H.; Hori, Y.; Fujita, T.; Nishimura, M.; Goto, T.; Okuhara, M. J. Antibiot. 1994, 47, 301.
5. (c) Shigematsu, N.; Ueda, H.; Takase, S.; Tanaka, H. J. Antibiot. 1994, 47, 311.
6. (d) Ueda, H.; Manda, T.; Matsumoto, S.; Mukumoto, S.; Nishigaki, F.; Kawamura, I.; Shimomura, K. J. Antibiot. 1994, 47, 315.
7. Masuoka, Y.; Nagai, A.; Shin-ya, K.; Furihata, K.; Nagai, K.; Suzuki, K.; Hayakawa, Y.; Seto, H. Tetrahedron Lett. 2001, 42, 41.
8. Townsend, P. A.; Crabb, S. J.; Davidson, S. M.; Johnson, P. W. M.; Packham, G.; Ganesan, A. The bicyclic depsipeptide family of histone deacetylase inhibitors. In Chemical Biology; Schreiber, S. L., Kapoor, T. M., Wess, G., Eds.; Wiley-VCH Verlag GmbH & Co.: Weinheim, Germany, 2007; Vol. 69, pp 3-720..
9. 50 HDAC inhibitory data for largazole.
10. Somech, R.; Israeli, S.; Simon, A. Cancer Treat. Rev. 2004, 30, 461.
11. (a) Miller, T. A.; Witter, D. J.; Belvedere, S. J. Med. Chem. 2003, 46, 5097.
12. (b) Moradei, O.; Maroun, C. R.; Paquin, I.; Vaisburg, A. Curr. Med. Chem.; Anti-Cancer Agents 2005, 5, 529.
13. (c) Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Nat. Rev. Drug Discovery 2006, 5, 769.
14. Minucci, S.; Pelicci, P. G. Nature Rev. Cancer 2006, 6, 38.
15. (a) Taunton, J.; Hassig, C. A.; Schreiber, S. L. Science 1996, 272, 408.
16. (b) Grozinger, C. M.; Hassig, C. A.; Schreiber, S. L. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4868.
17. (c) Johnstone, R. W. Nature Rev. Drug Discovery 2002, 1, 287.
18. (a) Yoshida, M.; Kijama, M.; Akita, M.; Beppu, T. J. Biol. Chem. 1990, 265, 17174.
19. (b) Yoshida, M.; Hoshikawa, Y.; Koseki, K.; Mori, K.; Beppu, T. J. Antibiot. 1990, 43, 1101.
20. (a) Or, Y. S.; Verdine, G. L.; Keegan, M. Preparation of Metabolite Derivatives of the HDAC Inhibitor FK228. PCT Int. Appl. WO 2007061939, 2007.
21. (b) Yurek-George, A.; Cecil, A. R. L.; Mo, A. H. K.; Wen, S.; Rogers, H.; Habens, F.; Maeda, S.; Yoshida, M.; Packham, G.; Ganesan, A. J. Med. Chem. 2007, 50, 5720.
22. (a) Johns, D. M.; Greshock, T. J.; Noguchi, Y.; Williams, R. M. Org. Lett. 2008, 10, 613.
23. (b) Greshock, T. J.; West, N.; Schreiber, S. L.; Bradner, J. E.; Williams, R. M.,unpublished results.
24. (a) Li, K. W.; Wu, J.; Xing, W.; Simon, J. A. J. Am. Chem. Soc. 1996, 118, 7237.
25. (b) Chen, Y.; Gambs, C.; Abe, Y.; Wentworth, P.; Janda, K. D. J. Org. Chem. 2003, 68, 8902.
26. (c) Yurek-George, A.; Habens, F.; Brimmell, M.; Packham, G.; Ganesan, A. J. Am. Chem. Soc. 2004, 126, 1030.
27. (a) Jeanguenat, A.; Seebach, D. J. Chem. Soc., Perkin Trans. 1 1991, 2291.
28. (b) Mulqueen, G. C.; Pattenden, D.; Whiting, D. A. Tetrahedron 1993, 49, 5359.
29. Smith, N. D.; Goodman, M. Org. Lett. 2003, 5, 1035.
30. (a) Videnov, G.; Kaiser, D.; Kempter, C.; Jung, G. Angew. Chem., Int. Ed. Engl. 1996, 35, 1503.
31. (b) Lange, U. E. W.; Schäfer, B.; Baucke, D.; Buschmann, E.; Mack, H. Tetrahedron Lett. 1999, 40, 7067.
32. Yurek-George, A.; Habens, F.; Brimmell, M.; Packham, G.; Ganesan, A. J. Am. Chem. Soc. 2004, 126, 1030.
33. 50 data, which have substantial variation between assays and are thus of limited utility and extensibility. We also note that the present synthesis is significantly higher yielding than that reported in ref 1b.
34. Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K.-H.; Nishiyama, M.; Nakajima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. Cancer Res. 2002, 62, 4916.
35. For several naturally occurring macrocyclic HDAC inhibitors, see :(a) Singh, S. B.; Zink, D. L.; Polishook, J. D.; Dombrowski, A. W.; Darkin-Rattray, S. J.; Schmatz, D. M.; Goetz, M. A. Tetrahedron Lett. 1996, 37, 8077.
36. (b) Nakao, Y.; Yoshida, S.; Matsunaga, S.; Shindoh, N.; Terada, Y.; Nagai, K.; Yamashita, J. K.; Ganesan, A.; van Soest, R. W. M.; Fusetani, N. Angew. Chem., Int. Ed. 2006, 45, 7553.
37. (c) Kijima, M.; Yoshida, M.; Sugita, K.; Horinouchi, S.; Beppu, T. J. Biol. Chem. 1993, 268, 22429.
38. (d) Tsuji, N.; Kobayashi, M.; Nagashima, K.; Wakisaka, Y.; Koizumi, K. J. Antibiot. 1976, 29, 1.